N

Nexstim Oyj
OMXH:NXTMH

Watchlist Manager
Nexstim Oyj
OMXH:NXTMH
Watchlist
Price: 8.36 EUR Market Closed
Market Cap: 59.9m EUR
Have any thoughts about
Nexstim Oyj?
Write Note

Nexstim Oyj
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nexstim Oyj
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
N
Nexstim Oyj
OMXH:NXTMH
Common Shares Outstanding
€6.8m
CAGR 3-Years
0%
CAGR 5-Years
30%
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Common Shares Outstanding
€26.6m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
M
Modulight Oyj
OMXH:MODU
Common Shares Outstanding
€42.6m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Common Shares Outstanding
€19.5m
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Common Shares Outstanding
€17.8m
CAGR 3-Years
10%
CAGR 5-Years
17%
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Common Shares Outstanding
€15.2m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
No Stocks Found

Nexstim Oyj
Glance View

Market Cap
56.6m EUR
Industry
Health Care

Nexstim Oyj engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen and currently employs 37 full-time employees. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.

NXTMH Intrinsic Value
6.19 EUR
Overvaluation 26%
Intrinsic Value
Price
N

See Also

What is Nexstim Oyj's Common Shares Outstanding?
Common Shares Outstanding
6.8m EUR

Based on the financial report for Jun 30, 2024, Nexstim Oyj's Common Shares Outstanding amounts to 6.8m EUR.

What is Nexstim Oyj's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
30%

Over the last year, the Common Shares Outstanding growth was 0%.

Back to Top